Pharma bro Martin Shkreli refuses to answer questions in Congress about AIDS drug price hike
Martin Shkreli, the former pharma executive who drastically increased the price of an AIDS drug, has appeared before Congress.
Turing Pharmaceuticals founder Martin Shkreli came under fire last year after buying the rights to 62-year-old drug Daraprim, which is used to treat conditions including AIDS-related toxoplasmosis, and jacking up the price to $750 a pill.
The 5500% price rise sparked outrage, but Shkreli refused to back down. He was removed as the company’s CEO after he was arrested over unrelated fraud allegations.
Shkreli appeared before US Congress today to answer questions about his company’s actions – but heeded his legal counsel’s advice to stay quiet about the incident.
The House of Representatives Committee on Oversight and Government Reform posed a number of questions to Shkreli, repeatedly exercising his right to remain silent.
Asked about his actions, he said: “On the advice of counsel, I invoke my Fifth Amendment privilege against self-incrimination, and respectfully decline your question.”plead the fifth.”
Asked about AIDS patients struggling to afford their medication, he said: “On the advice of counsel, I invoke my Fifth Amendment privilege against self-incrimination, and respectfully decline your question.”
When challenged about his refusal to cooperate, he told a lawmaker: “I intend to follow the advice of my counsel, not yours.”
The former CEO seemed detached throughout the hearing, smirking at many of the questions as he declined to answer – and even giggling at one point, while a lawmaker was speaking about the impact of Shkreli’s money-grabbing actions.
US Representative Elijah Cummings rebuked him for the laughter, firing back: “It’s not funny, Mr Shkreli.”
MyPinkNews members are invited to comment on articles to discuss the content we publish, or debate issues more generally. Please familiarise yourself with our community guidelines to ensure that our community remains a safe and inclusive space for all.